PROVEN RESULTS
ELIGIBLE PATIENTS
Superior on all measures at Week 12 in a double-blind RCT (N=60): better SCORAD, TEWL, DLQI, hydration, and skin pH (Prakoeswa, 2025). Confirmed in a second independent RCT (Canchy et al., ISAD, 2024).
Yes. Tested under dermatological and paediatric control from the first days of life, with high response rates and good tolerance (Canchy et al., WCPD, 2025).
TEWL improvement vs urea is measurable from Week 4. Significant differences in SCORAD, DLQI, and hydration emerge between Week 8 and Week 12 (Prakoeswa, 2025).
Yes — 31% less corticosteroid by weight vs standard emollient in a 28-day RCT (N=119; p=0.041) (Zelenkova, 2023).
Studies across Fitzpatrick I–VI confirm increased NMF levels and improved itch intensity across all skin tones (La Roche-Posay, AAD, 2025).
Before (D0)
After (D28)
Tested on skins with atopic background
Visible efficacy
Effect after 6h, dry skin relief for long-lasting hydration
Itch control
For a better quality of life day & night
Moisturizing effect on all skin tones
Long lasting relief for ultra dry to atopic prone skin
KEY ACTIVE COMPLEX
Neurobioma: Proteasyl + Aqua Posae Filiformis + Microresyl
Routine
Patient Services
L'Oréal Dermatological Beauty Pro is a digital community empowering healthcare professionals to improve their daily practice of dermatology through cutting edge research, science and education on skin and hair care.
Sign Up For Free TodayAlready registered? Log in